|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Arab women tended to be younger (P = 0.013), more disadvantaged (P < 0.001), were more likely to have symptomatic rather than screen-detected breast cancer (P < 0.001), had a higher rate of high grade (P = 0.021), HER2-positive (P = 0.025) breast cancer compared to Australian-born women or others.
|
31845467 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Intermittent first- and second-line chemotherapy in patients with HER2-negative advanced breast cancer showed a trend for worse impact on QoL compared to continuous chemotherapy, with neither significant nor meaningful differences in course.
|
31782032 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this Review, we describe the current role of HER2-targeted therapies beyond breast cancer and also highlight the potential of novel HER2-targeted agents that are currently in clinical development.
|
31548601 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study indicates that aptamers mediating targeted drug delivery by GNVs represent a promising strategy for HER2<sup>+</sup> breast cancer therapy.
|
31134823 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
p16 promoter methylation, expression, and its association with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 subtype of breast carcinoma.
|
31603125 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
From the discovery of endocrine and HER2 targeted therapies, to multigene arrays in chemotherapy for more specific patient selection, to radiomics and genetic subtyping, targeted therapies and precision medicine continue to push the management of breast cancer toward more individualized care.
|
31757313 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
OMclin1 and OMclin2 were evaluated for 646 postmenopausal patients with ER-positive/HER2-negative primary breast cancer with 0-3 involved lymph nodes in TransATAC.
|
31641007 |
2020 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In postmenopausal women, Luminal A (OR 2.35, 95% CI 2.01-2.75), Luminal B HER2 negative (OR 1.81, 95% CI 1.46-2.25) and triple-negative subtype (OR 2.25, 95% CI 1.85-2.72) showed higher risk of breast cancer in obese II women.
|
31628583 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to retrospectively investigate the response to trastuzumab in breast cancer patients in terms of the potential roles of several oncogenic pathways (phosphatase and tensin homolog (PTEN) and phosphatidylinositol 3-kinase (PI3K)) in relation to HER2 status.
|
31786856 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Genomic tests can identify ER-positive HER2-negative localized breast cancer patients who may not benefit from adjuvant chemotherapy.
|
31790959 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Because dual-agent HER2 blockade demonstrated a survival benefit in breast cancer, we conducted a phase II feasibility study of trastuzumab and pertuzumab added to neoadjuvant chemoradiotherapy (nCRT) in patients with EAC.
|
31809243 |
2020 |
|
Breast Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Notably, intermediate HER2 expression predicted poorer RFS in EBC patients aged ≥ 55 years (hazard ratio 1.95; p = 0.042) in multivariate Cox analysis but did not affect RFS in those aged < 55 years.
|
31811505 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2-positive primary breast cancer patients treated using NAC containing trastuzumab were enrolled between September 2006 and June 2017 at the Osaka Breast Clinic.
|
31574500 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In multivariate analysis, histologic grade 3 (p = 0.014), presence of extracranial metastasis (p < 0.001), the number of BM (>4; p = 0.002), hormone receptor negativity (p = 0.005), HER2-negativity (p = 0.003), and shorter time interval (<30 months) between BC and BM diagnosis (p = 0.007) were associated with inferior OS.
|
31677532 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Expert opinion</b>: Pertuzumab is a key drug for the treatment of HER2-positive metastatic or early breast cancer.
|
30884986 |
2020 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To investigate possible associations between quantitative apparent diffusion coefficient (ADC) metrics derived from whole-lesion histogram analysis and breast cancer recurrence risk in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative breast cancer who underwent the Oncotype DX assay.
|
31385051 |
2020 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Collectively these data define HER2 mutations as a therapeutic target in breast cancer and suggest that co-existence of additional HER signaling alterations may promote both de novo and acquired resistance to neratinib.
|
31806627 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Among 16 702 patients recorded in the ESME MBC database, 10 595 had an initially localised breast cancer with hormone receptor (HR) and HER2 status available, with a metastatic recurrence.Median follow up was 56 months.
|
31675683 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MCM2 expression was studied in 142 primary HER2-amplified breast carcinomas by applying a novel fluoro-chromogenic immunohistochemistry and tailored digital image analysis to determine labelling index (MCM2-LI).
|
30358612 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Docetaxel, cyclophosphamide and trastuzumab might be an option for primary systemic therapy in human epidermal growth factor receptor-2-positive early breast cancer.
|
31821506 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Postmenopausal women with stage I-IIIB HR+/HER2- breast cancer were randomized to a 2-week lead-in of abemaciclib, anastrozole, or abemaciclib plus anastrozole followed by 14 weeks of the combination.
|
31615937 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Transcription Factor Activator Protein 2γ (TFAP2C, AP-2γ) governs luminal breast cancer phenotype through direct and indirect regulation of ERα and ERα-associated genes, GATA3, FOXA1, EGFR, CDH1, DSP, KRT7, FBP1, MYB, RET, KRT8, MUC1, and ERBB2-genes which are responsible for the luminal signature in breast cancer.
|
31636386 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although trastuzumab is one of the most effective therapeutic antibodies in HER2-overexpressing breast cancer, a significant number of patients do not benefit from this therapy due to inherent or acquired resistance mechanisms.
|
31804840 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
HER2-targeting monoclonal antibodies resulted in longer survival of HER2<sup>+</sup> breast cancer.
|
31691197 |
2020 |
|
Breast Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Addition of rNDV directly to iDCs culture induced DC maturation, as demonstrated by the increased expression of costimulatory and antigen-presenting molecules as well as the production of type I interferons (IFNs). rNDV infection of the HER-2 positive human breast cancer cell line (SKBR3) resulted in apoptotic cell death, release of proinflammatory cytokines, and danger-associated molecular pattern molecules (DAMPs) including high-mobility group protein B1 (HMGB1) and heat shock protein 70 (HSP70).
|
31584185 |
2020 |